Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LPGAT1 antisense RNA 1 (LPGAT1-AS1) is a long non-coding RNA (lncRNA) transcribed from the strand opposite to the LPGAT1 protein-coding gene[4][6]. Antisense RNAs like LPGAT1-AS1 are generally understood to regulate the expression of their corresponding sense genes through mechanisms such as transcriptional interference or RNA duplex formation, but no experimentally validated biological function, disease relevance, or pharmacological interaction has been published for LPGAT1-AS1 to date[4][6]. It is not classified as a therapeutic target, enzyme, receptor, or transporter. There are no known drugs, mechanisms of drug action, or biomarker uses associated specifically with LPGAT1-AS1, and no safety or therapeutic concerns have been described. The genomic location is chr1:211829476-211853704 (hg38)[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LPGAT1 antisense RNA 1 (LPGAT1-AS1).